Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease

Expert Review of Molecular Diagnostics

Volumn 4, Issue 1, 2004, Pages 63-69

  Chang, Carol Y ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimerr's disease; Dementia; Early diagnosis; Neuroimaging

Indexed keywords

ALZHEIMER DISEASE; CONFERENCE PAPER; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MORBIDITY; PATIENT CARE; PREVALENCE; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; BRAIN; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0347132569     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.1.63     Document Type: Conference Paper

References (50)

1. Evans DA. Estimated Prevalence of Alzheimer's Disease in the US. Milbank Q 68, 267-289 (1990).
2. Bachman DL, Wolf PA, Linn RT et al. Incidence of dementia and probably Alzheimer's disease in a general population: the Framingham study. Neurology 43, 515-519 (1993).
3. Jorm AF. The Epidemiology of Alzheimer's Disease and Related Disorders. Chapman & Hall, London, UK (1990).
4. Carr DB, Goate A, Phil D, Morris JC. Current concepts in the pathogenesis of Alzheimer's disease. Am. J. Med 103(Suppl. 3A), S3-S10 (1997).
5. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am. J. Pub. Health 84, 1261-1264 (1994).
6. Hof PR, Bierer LM, Perl DP et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Arch. Neurol. 49, 946 (1992).
7. Arnold SE, Hyman BT, Flory J et al. The topographical and neuroanatomical distribution of neurofkibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex 1, 103 (1991).
8. Ross GW, Abbott RD, Petrovich H et al. Frequency and characteristics of silent dementia among elderly Japanese-American men: the Honolulu-Asia Aging Study. JAMA 277, 800-805 (1997).
9. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
10. Reichman WE, Cummings JL. Neuropsychiatric disorders in geriatric practice. In: Practice of Geriatrics. Duthie (Ed.), WB Saunders, 267-278 (1998).
11. Folstein MF, Folstein SE, McHugh PR, Mini-mental state. J. Psychiatr. Res. 12, 189-198 (1975).
12. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34(7), 939-944 (1984).
13. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer's disease: a look to the future. Radiology 226(2), 315-336 (2003). Provides a good overview of different neuroimagaing modalities in the diagnosis of Alzheimer's disease.
14. Friedland RP, Jagust WJ. Positron and single photon emission tomography in the differential diagnosis of dementia. In: Positron Emission Tomography in Dementia. Duara R (Ed.), Wiley-Liss Inc., NY, USA, 161-177 (1990).
15. Haxby JV. Resting state regional cerebral metabolism in dementia of the Alzheimer type. In: Positron Emission Tomograpby in Dementia. Duara R (Ed.), Wiley-Liss Inc, NY, USA, 93-116 (1990).
16. Mazziota JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin. Nucl. Med. 22, 233-246 (1992).
17. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis. Assoc. Disord 9, 6-16 (1995).
18. Silverman DHS, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin. Positron Imaging 2, 119-130 (1999).
19. Pietrini P, Alexander GE, Furey ML et al. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Int. J. Pyschophysiol. 37, 87-98 (2000).
20. Small GW, Mazziota JC, Collins MT et al. Apolipoprotein E Type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 273, 942-947 (1995).
21. Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N. Engl. J. Med 334, 752-758 (1996).
22. 18F] fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol. Imag. Biol. 4(4), 283-293 (2002).
23. Hoffman JM, Welsh-Bohmer KA, Hanson M et al. FDG PET imaging in patients with pathologically verified dementia. J. Nucl Med 41, 1920-1928 (2000).
24. Silverman DHS, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120-2127 (2001). International multicenter study evaluating the role of positron emission tomography in the evaluation of dementia.
25. Kennedy AM, Frackowiak RSJ, Newman SK et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186, 17-20 (1995).
26. Silverman DHS, Gambhir SS, Huang HC et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J. Nucl. Med. 43, 253-266 (2002). Compares costs and benefits and provides useful algorithm for determining when to obtain positron emission tomography study for evaluation of cognitive decline.
27. Ryan DH. Misdiagnosis in dementia: comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. Int. J. Geriatr. Psychiatry 9, 141-147 (1994).
28. Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treament with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin. Ther. 178-193 (2003).
29. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA 278, 1363-1371 (1997).
30. Knapp MG, Knopman DS, Solomon PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease: the Tacrine Study Group. JAMA 271, 985-991 (1994).
31. Rogers SL, Friedhof LT, Apter JT et al. The efficacy and safety of donepezil patients with Alzheimer's disease: results of a US muticentre, randomized, blind, placebo controlled trial: the Donepezil Study Group. Dementia 7, 293-303, (1996).
32. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension: the Galantamine USA-1 Study Group. Neurology 54, 2261-2268, (2000).
33. Birks J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 2, CD00119 (2000).
34. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial: the international Donepezil Study Group. Dement. Geriatr. Cogn. Disord 10, 237-244 (1999).
35. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease: the ENA 713 B352 Study Group. Int. J. Geriatr. Psychopharmacol. 1, 55-65 (1998).
36. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. Brit. Med. J. 318, 633-638 (1999).
37. Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15 week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med. 158, 1021-1031 (1998).
38. Knopman D, Schneider LS, Davis K et al. Long-term tacrine (Cognex) treament effects on nursing home placement and mortality: the Tacrine Study Group. Neurology 47, 166-177 (1996).
39. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin. Ther. 20, 838-850 (1998).
40. Brodaty H, McGilchrist C, Harris L et al. Time until institutionalization and death in patients with dementia. Arch. Neurol. 50, 643-650 (1993).
41. Brodaty H, Gresham M. Effect of a training programme to reduce stress in carers of patients with dementia. Br. Med. J. 299, 1375-1379 (1989).
42. Lawton MP, Brody EM, Saperstein AR. A controlled study of respite service for caregivers of Alzheimer's patients. Gerontologist 29, 8-16 (1989).
43. Mohide EA, Pringie DM, Streiner DL et al. A randomized trial of family caregiver support in the home management of dementia. J. Am. Geriatr. Soc. 38, 446-454 (1990).
44. Mittelman MS, Ferris SH, Shulman E et al. A family intervention to delay nursing home placement of patients with Alzheimer's disease. JAMA 276(21), 1725-1731 (1996). Well-controlled randomized study of how intervention prolongs placement into nursing homes.
45. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psychiatry 49, 289-299 (2001).
46. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8, 67-75 (1998).
47. Imbimbo BP, Verdelli G, Martelli P, Marchesini D. Two-year treatment of Alzheimer's disease with eptastigmine. Dement. Geriatr Cogn. Disord 10, 139-147 (1999).
48. Fago JP. Dementia: causes, evaluation and management. Hosp. Pract. 36, 59-69 (2001).
49. Rinne JO, Kaasinen V, Jarvenpaa T et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. 74(1), 113-115 (2003).
50. Kopcho LM, Ma J, Marcinkeviciene J et al. Comparative studies of active site-ligand interactions among various recombinant constructs of human β-amyloid precursor protein cleaving enzyme. Arch. Biochem. Biophys. 410(2), 307-316 (2003).